PubMed Health⌕ Search

Biomedical subjects

J Hasik

Publications and source records attributed to J Hasik.

At least 19 recordsLinked to original sources

Seasonal prevention of duodenal ulcer recurrences with pirenzepine.

Seasonal accumulation of duodenal ulcer recurrences suggests that maintenance therapy could be limited to the more risky periods. We carried out a 2-year, multi-centre, randomized, double blind study in 250 patients in whom the last ulcer proved to be healed at the endoscopy on entry. One-hundred-and-twenty-six patients in group A were given pirenzepine 2 X 25 mg while 124 in group B had 2 X 50 mg daily from the beginning of January to the end of March, and from the beginning of September to the end of November for two consecutive years. Test endoscopies were performed each year at the end of February, May and November. Both groups proved to be well comparable. Thirty-five patients dropped out from group A in the first and 10 in the second year; in group B 27 and 29, respectively. As the effect did not show any dose relation, the four yearly cycles were summarized. Recurrence rate checked in May was 22.1% while in both pirenzepine protected months it was 11.3% (p less than 0.0005) and 13.4% (p less than 0.001), respectively. We conclude that pirenzepine administered in the risky seasons prevents the peak ulcer incidence and reduces the recurrence rate to a level lower than in the non-risky season. Thus pirenzepine is effective in ulcer prevention even if administered in an interrupted manner.

Adult↗

[Clinical and metabolic evaluation of patients with chronic pancreatitis following a special peptide diet].

The purpose of present investigations was to evaluate the effect of peptide diet upon clinical and metabolic course of chronic pancreatitis. Nitrogen, potassium and sodium balances were done for 24 days in 4 patients with chronic pancreatitis fed with peptide diet as well as in 5 patients fed with normal low fat diet. Administration of peptide diet improved protein nutritional status of all patients, due to better absorption of aminoacid components and increased nitrogen retention. On the basis of obtained results the authors discuss possibility of dietary treatment of chronic pancreatitis with peptide diet.

Adult↗

Ranitidine in the maintenance therapy of gastro-duodenal ulcer disease: Polish open multicentre study.

Our first stage 3-week trial (6) and second stage up to 6 weeks (7) showed that ranitidine provides the highest healing rate of 97% for duodenal and 95% for gastric ulcer. The study has been now prolonged for one year to assess the efficacy of maintenance therapy. Out of 258 patients who completed the second stage 232 voluntarily entered the open stage 3 in which they were given a single dose R 150 mg nocte, and were endoscopied after 4, 8 and 12 months. There were 153 duodenal and 79 gastric ulcers. 191 patients completed the study; no undesired effects were found and there was no medical reason to withdraw the drug from the long term use. Recurrent ulcer was found in 33.3% out of 126 duodenal ulcer cases, and in 29.2% out of 65 gastric ulcer patients who completed stage three. Sixteen percent of recurrent gastric ulcers and 26% of duodenal ulcers were asymptomatic. Recurrence rate was about twice as high in smokers as in non-smokers. These findings were compared with our long-term endoscopic survey of the natural history of peptic ulcer disease (8) in which yearly recurrence rate of duodenal ulcer was 68.4% and of gastric ulcers 73.5%, 14% of them being painless. This indicates that R is fairly well tolerated in long term use and may be useful to curb the ulcer recurrence rate.

Adult↗

[Double-blind study on therapy with new drugs in stomach and duodenal ulcers].

Patients with ulcers of the stomach and the duodenum were treated with Pirenzepin and the new H2-inhibitor Renitidin. The effects were evaluated on the basis of a double blind trial. After the endoscopic diagnosis repeated examinations were practiced until three weeks after the beginning of the treatment. The best results were found in duodenal ulcers after treatment with Renitidin. 86,6% of the ulcers were healed after 3 weeks of treatment. This results was statistically significant compared with a group of patients treated with a placebo. With gastrozepin 77,2% of patients were successfully treated. In ulcers of the stomach the results were not so good and statistically insignificant. Side effects were not found. Until now it is not possible to decide which substance guarantees better results.

Adult↗